Full metadata record
DC FieldValueLanguage
dc.creatorBanaschewski, T. (Tobias)-
dc.creatorJohnson, M. (Mats)-
dc.creatorNagy, P. (Peter)-
dc.creatorHernández-Otero, I. (Isabel)-
dc.creatorSoutullo-Esperón, C. (César Alejandro)-
dc.creatorYan, B. (Brian)-
dc.creatorZuddas, A. (Alessandro)-
dc.creatorCoghill, D. (David)-
dc.date.accessioned2022-11-08T11:01:11Z-
dc.date.available2022-11-08T11:01:11Z-
dc.date.issued2018-
dc.identifier.citationBanaschewski, T. (Tobias); Johnson, M. (Mats); Nagy, P. (Peter); et al. "Growth and puberty in a 2-year open-label study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder". Cns drugs. 32 (5), 2018, 455 - 467es_ES
dc.identifier.issn1172-7047-
dc.identifier.urihttps://hdl.handle.net/10171/64612-
dc.description.abstractBackground: Stimulant medications for the treatment of attention-deficit/hyperactivity disorder have a history of safe and effective use; however, concerns exist that they may adversely affect growth trajectories in children and adolescents. Objective: The objective of this study was to evaluate the longer-term effects of lisdexamfetamine dimesylate on weight, height, body mass index and pubertal development in children and adolescents with attention-deficit/hyperactivity disorder. Methods: Children and adolescents aged 6–17 years with attention-deficit/hyperactivity disorder took open-label lisdexamfetamine dimesylate (30, 50 or 70 mg/day) in this open-label 2-year safety and efficacy study. Safety evaluations included treatment-emergent adverse events, measurement of weight, height and body mass index, and selfreported pubertal status using Tanner staging. Results: The safety analysis population comprised all enrolled participants (N = 314) and 191 (60.8%) completed the study. Weight decrease was reported as a treatmentemergent adverse event in 63 participants (20.1%) and two participants (0.6%) discontinued the study as a result of treatment-emergent adverse events of weight decrease.es_ES
dc.description.sponsorshipThis study was funded by Shire Development LLC. Writing and editing assistance for this paper was provided by Oxford PharmaGenesis, funded by Shire International GmbH. Shire International GmbH also funded open access.es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectStimulant medicationses_ES
dc.subjectTreatment of attention-deficit/hyperactivity disorderes_ES
dc.subjectGrowth trajectorieses_ES
dc.subjectChildrenes_ES
dc.subjectAdolescentses_ES
dc.titleGrowth and puberty in a 2-year open-label study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorderes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.es_ES
dc.identifier.doi10.1007/s40263-018-0514-8-
dadun.citation.endingPage467es_ES
dadun.citation.number5es_ES
dadun.citation.publicationNameCns drugses_ES
dadun.citation.startingPage455es_ES
dadun.citation.volume32es_ES

Files in This Item:
Thumbnail
File
s40263-018-0514-8.pdf
Description
Size
682.47 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.